Published 2 months ago

After US approval, Japan OKs its first Alzheimer's drug. Leqembi was developed by Eisai and Biogen

Japan's health ministry has approved Leqembi, a drug for Alzheimer's disease, making it the first country with a rapidly aging population to have a treatment for the disease.
Leqembi, developed by Japanese drugmaker Eisai Co. And US biotechnology firm Biogen Inc., is designed for patients in the early stages of Alzheimer's, helping to slow their cognitive decline. The approval was announced by Prime Minister Fumio Kishida.
The number of dementia patients aged 65 or older in Japan is expected to rise to 7 million by 2025, highlighting the urgent need for treatments like Leqembi. Eisai Co. Is dedicated to providing this new treatment to individuals and their families.

Insights by Ground AI

Does this summary seem wrong?

More
Filters

29 Articles

All

Left

Center

Right

abc News

After US approval, Japan OKs Leqembi, its first Alzheimer's drug, developed by Eisai and Biogen

Japan’s health ministry has approved Leqembi, a drug for Alzheimer’s decease that was jointly developed by Japanese and U.S. pharmaceutical companies

2 months ago·United States

Read Full Article

National Post

After US approval, Japan OKs Leqembi, its first Alzheimer's drug, developed by Eisai and Biogen

TOKYO (AP) -- Japan's health ministry has approved Leqembi, a drug for Alzheimer's disease that was jointly developed by Japanese and U.S. pharmaceutical companies. It's the first drug for treatment of the disease in a country with a rapidly aging population.

2 months ago·Canada

Read Full Article

Financial Post

After US approval, Japan OKs Leqembi, its first Alzheimer's drug, developed by Eisai and Biogen

2 months ago·Canada

Read Full Article

Winnipeg Free Press

After US approval, Japan OKs Leqembi, its first Alzheimer's drug, developed by Eisai and Biogen

TOKYO (AP) — Japan’s health ministry has approved Leqembi, a drug for Alzheimer’s disease that was jointly developed by Japanese and U.S. pharmaceutical companies. It’s the first drug for treatment […]

2 months ago·Winnipeg, Canada

Read Full Article

Benzinga

Japan's Regulatory Authority Approves Biogen/Eisai's Alzheimer Treatment Leqembi - Eisai Co (OTC:ESALF), Biogen (NASDAQ:BIIB)

Eisai Co Ltd (OTC: ESALY) (OTC: ESALF) and Biogen Inc (NASDAQ: BIIB) announced that humanized anti-soluble aggregated amyloid-beta (Aβ) monoclonal antibody Leqembi Intravenous Infusion (200 mg, 500mg, lecanemab) has been approved in Japan as a treatment for slowing progression of mild cognitive impairment and mild dementia due to Alzheimer's disease (AD). Leqembi is a humanized immunoglobulin gamma 1 (IgG1) monoclonal antibody directed against a…

2 months ago·New York, United States

Read Full Article

News 4 JAX

After US approval, Japan OKs its first Alzheimer's drug. Leqembi was developed by Eisai and Biogen

Japan's health ministry has approved Leqembi, a drug for Alzheimer’s disease that was jointly developed by Japanese and U.S. pharmaceutical companies. It's the first drug for treatment of the disease in a country with a rapidly aging population.Developed by Japanese drugmaker Eisai Co. and U.S. biotechnology firm Biogen Inc., the drug's approval in Japan comes two months after it was endorsed by the U.S. Food and Drug Administration. Leqembi is …

2 months ago·Jacksonville, United States

Read Full Article

Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/year

Coverage Details

Total News Sources0

Leaning Left8Leaning Right4Center9Last Updated2 months agoBias Distribution

43% Center

Bias Distribution

43% of the sources are Center

45% Center

Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

Sources are mostly out of (0)

After US approval, Japan OKs its first Alzheimer's drug. Leqembi was developed by Eisai and Biogen

29 Articles

29 Articles

After US approval, Japan OKs Leqembi, its first Alzheimer's drug, developed by Eisai and Biogen

After US approval, Japan OKs Leqembi, its first Alzheimer's drug, developed by Eisai and Biogen

After US approval, Japan OKs Leqembi, its first Alzheimer's drug, developed by Eisai and Biogen

After US approval, Japan OKs Leqembi, its first Alzheimer's drug, developed by Eisai and Biogen

After US approval, Japan OKs Leqembi, its first Alzheimer's drug, developed by Eisai and Biogen

After US approval, Japan OKs Leqembi, its first Alzheimer's drug, developed by Eisai and Biogen

After US approval, Japan OKs Leqembi, its first Alzheimer's drug, developed by Eisai and Biogen

After US approval, Japan OKs Leqembi, its first Alzheimer's drug, developed by Eisai and Biogen

Japan's Regulatory Authority Approves Biogen/Eisai's Alzheimer Treatment Leqembi - Eisai Co (OTC:ESALF), Biogen (NASDAQ:BIIB)

Japan's Regulatory Authority Approves Biogen/Eisai's Alzheimer Treatment Leqembi - Eisai Co (OTC:ESALF), Biogen (NASDAQ:BIIB)

After US approval, Japan OKs its first Alzheimer's drug. Leqembi was developed by Eisai and Biogen

After US approval, Japan OKs its first Alzheimer's drug. Leqembi was developed by Eisai and Biogen

Coverage Details

Bias Distribution

Ownership

Similar News Topics

Similar News Topics